# Genoa Ventures

> Genoa Ventures is a VC fund backing Biotechnology and Health Care. See 40 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 40
- Last investment: Jul 2026
- Lead investor: 38%
- Fund size: $84M
- Last fund: Jul 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/genoaventures
- X (Twitter): https://twitter.com/genoaventures
- Website: http://www.genoavc.com/

Genoa Ventures is a VC fund in San Francisco focused on Biotechnology and Health Care. Genoa Ventures invests in early-stage life sciences technology companies. They fund entrepreneurs and companies looking to change the way science gets done with new tools and technologies. Sector focus areas include research tools, molecular diagnostics, synthetic biology, and industrial biology.Genoa Ventures was founded in 2014 by Jenny Rookeand is based in San Francisco, California, United States.

## Contacts

5 contacts available for Genoa Ventures. Shizune tracks 5 team members at Genoa Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/5-prime-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.5M–$6M |
| Series A | $9.5M–$33M |
| Series B | $7.1M–$34M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 24 | 60% |
| Health Care | 13 | 33% |
| Life Science | 5 | 13% |
| Medical | 4 | 10% |
| Pharmaceutical | 4 | 10% |

37 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 16 | 40% |
| Series B | 9 | 23% |
| Seed | 8 | 20% |
| Series C | 4 | 10% |
| Funding Round | 3 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 26 | 65% |
| France | 1 | 3% |
| United Kingdom | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jenny Rooke | Founder & Managing Director | 27 | https://shizune.co/investors/profile/jenny-rooke |
| Jonathan Burbaum | Venture Partner | 0 | https://shizune.co/investors/profile/jonathan-burbaum |
| Landon Merrill | principal | 1 | https://shizune.co/investors/profile/landon-merrill-ca74 |
| Paul Conley | Partner | 22 | https://shizune.co/investors/profile/dr-paul-conley |
| William (Bill) Hyun | Venture Partner | 0 | https://shizune.co/investors/profile/bill-hyun |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Epitel | Epitel is a digital health company developing a wearable, wireless EEG monitoring platform to provide accessible, affordable, and reliable for seizure detection. | $26M | Series B | Jul 28, 2026 |  |
| Tropic Biosciences | At Tropic Biosciences, They develop high-performing commercial varieties of tropical crops which promote grower wellbeing, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques. | $105M | Series C | Mar 12, 2026 |  |
| Hermes Biosciences | Hermes Biosciences describes a benchtop, hands-off extracellular vesicle isolation system designed to purify exosomes quickly, efficiently, and reproducibly from any bodily fluid or cell culture media. This technology aims to advance research into exosome function and support clinical applications in oncology, degenerative disease, and regenerativemedicine. | $6M | Seed | Nov 18, 2025 |  |
| Aqtual | Aqtual is a biotechnology diagnostics platform that provides healthcare solutions, novel technology and biochemistry for chronic disease. | $31M | Series B | Jul 10, 2025 |  |
| Alida Biosciences | Alida Biosciences is a biotech company creating RNA analysis tools to improve human health. The company was founded in 2020 and is headquartered in San Diego, CA. | $7.5M | Series A | Jun 12, 2024 |  |
| Aqtual | Aqtual is a biotechnology diagnostics platform that provides healthcare solutions, novel technology and biochemistry for chronic disease. | $16M | Series A | Oct 31, 2023 |  |
| BRAINBox Solutions | BRAINBox provides objective evidence of injury and prediction of patient recovery. BRAINBox Solutions' multi-modality approach is led by the leaders in the industry. It includes blood biomarker panels available on a point of care instrument and standard laboratory systems. | $7.1M | Series B | Oct 30, 2023 |  |
| BrightSpec | LabBrightSpec addresses high-value, time-sensitive analytical chemistry challenges that are not well addressed by other spectroscopy techniques and instruments. It provides innovative laboratory services in order to deliver immediate results to potential customers of our instrumentation products. They are based in Charlottesville, Virginia,about two hours from Washington, DC. The BrightSpec Fourier transform molecular rotational resonance (FT-MRR) product platform is based on technology developed at the University of Virginia by Brooks Pate and his team, several of whom now work at BrightSpec. They offer FT-MRR product configurations for analytical chemistry and gas sensing in manufacturing process control, quality control, environmental monitoring, and formulation research. | $18.4M | Series C | Dec 14, 2022 |  |
| ZwitterCo | ZwitterCo provides revolutionary membrane solutions for the treatment of highly-impaired wastewater. | $33M | Series A | Sep 15, 2022 |  |
| Fellow Health | Fellow Health provides peer-reviewed, clinical semen analysis solutions that patients can conveniently perform at home. Their services cover full semen analysis, post-vasectomy semen analysis, and cryopreservation. | $24M | Series A | Aug 01, 2022 |  |

10 of 40 investments shown.

## Co-investors
- [Vertical Venture Partners](https://shizune.co/investors/profile/vertical-venture-partners) — VC Fund, 6 deals together
- [Anzu Partners](https://shizune.co/investors/profile/anzu-partner) — VC Fund, 4 deals together
- [True Ventures](https://shizune.co/investors/profile/true-ventures) — VC Fund, 4 deals together
- [Aliment Capital](https://shizune.co/investors/profile/aliment-capital) — VC Fund, 3 deals together
- [Amplify Partners](https://shizune.co/investors/profile/amplify-partners) — VC Fund, 3 deals together
- [DCVC](https://shizune.co/investors/profile/data-collective) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Kima Ventures](https://shizune.co/investors/profile/kima-ventures) — VC Fund
- [Motier Ventures](https://shizune.co/investors/profile/motier-ventures) — VC Fund

## Featured in investor lists
- [Life Science Investors in France](https://shizune.co/investors/life-science-investors-france)
- [Life Science VC Funds in France](https://shizune.co/investors/life-science-vc-funds-france)

## FAQ

### What does Genoa Ventures invest in?

Genoa Ventures invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Series B stage. Most of the 40 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Genoa Ventures's check size?

Genoa Ventures typically joins rounds of $1.5M–$6M at Seed, $9.5M–$33M at Series A and $7.1M–$34M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Genoa Ventures participates in.

### How do I contact Genoa Ventures?

Public channels for Genoa Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Genoa Ventures?

The team at Genoa Ventures includes Jenny Rooke (Founder & Managing Director), Jonathan Burbaum (Venture Partner) and Landon Merrill (principal). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co